Medical Care
Biosimilars Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Sep 11, 24
- ID: 549573
- Pages: 111
- Figures: 180
- Views: 1
The global market for Biosimilars Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biosimilars Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Biosimilars Treatment by region & country, by Type, and by Application.
The Biosimilars Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars Treatment.
Market Segmentation
By Company
Bayer
Eli Lily, Inc.
Pfizer, Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Amgen Inc.
Biocon
Dr. Reddy’s Laboratories
Roche Ltd.
Celltrion, Inc.
Samsung Bioepis
Segment by Type:
Recombinant Non – Glycosylated Proteins
Recombinant Glycosylated Proteins
Recombinant Peptides
Segment by Application
Oncology
Chronic and Autoimmune Disease
Blood Disorders
Growth Hormone Disease
Infectious Disease
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Biosimilars Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Biosimilars Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Biosimilars Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biosimilars Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Biosimilars Treatment by region & country, by Type, and by Application.
The Biosimilars Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars Treatment.
Market Segmentation
By Company
Bayer
Eli Lily, Inc.
Pfizer, Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Amgen Inc.
Biocon
Dr. Reddy’s Laboratories
Roche Ltd.
Celltrion, Inc.
Samsung Bioepis
Segment by Type:
Recombinant Non – Glycosylated Proteins
Recombinant Glycosylated Proteins
Recombinant Peptides
Segment by Application
Oncology
Chronic and Autoimmune Disease
Blood Disorders
Growth Hormone Disease
Infectious Disease
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Biosimilars Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Biosimilars Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Biosimilars Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Biosimilars Treatment Product Introduction
1.2 Global Biosimilars Treatment Market Size Forecast
1.3 Biosimilars Treatment Market Trends & Drivers
1.3.1 Biosimilars Treatment Industry Trends
1.3.2 Biosimilars Treatment Market Drivers & Opportunity
1.3.3 Biosimilars Treatment Market Challenges
1.3.4 Biosimilars Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Biosimilars Treatment Players Revenue Ranking (2023)
2.2 Global Biosimilars Treatment Revenue by Company (2019-2024)
2.3 Key Companies Biosimilars Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Biosimilars Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Biosimilars Treatment
2.6 Biosimilars Treatment Market Competitive Analysis
2.6.1 Biosimilars Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Biosimilars Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Recombinant Non – Glycosylated Proteins
3.1.2 Recombinant Glycosylated Proteins
3.1.3 Recombinant Peptides
3.2 Global Biosimilars Treatment Sales Value by Type
3.2.1 Global Biosimilars Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Biosimilars Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Biosimilars Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Oncology
4.1.2 Chronic and Autoimmune Disease
4.1.3 Blood Disorders
4.1.4 Growth Hormone Disease
4.1.5 Infectious Disease
4.2 Global Biosimilars Treatment Sales Value by Application
4.2.1 Global Biosimilars Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Biosimilars Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Biosimilars Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Biosimilars Treatment Sales Value by Region
5.1.1 Global Biosimilars Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Biosimilars Treatment Sales Value by Region (2019-2024)
5.1.3 Global Biosimilars Treatment Sales Value by Region (2025-2030)
5.1.4 Global Biosimilars Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Biosimilars Treatment Sales Value, 2019-2030
5.2.2 North America Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Biosimilars Treatment Sales Value, 2019-2030
5.3.2 Europe Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Biosimilars Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Biosimilars Treatment Sales Value, 2019-2030
5.5.2 South America Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Biosimilars Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Biosimilars Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Biosimilars Treatment Sales Value
6.3 United States
6.3.1 United States Biosimilars Treatment Sales Value, 2019-2030
6.3.2 United States Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Biosimilars Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Biosimilars Treatment Sales Value, 2019-2030
6.4.2 Europe Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Biosimilars Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Biosimilars Treatment Sales Value, 2019-2030
6.5.2 China Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Biosimilars Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Biosimilars Treatment Sales Value, 2019-2030
6.6.2 Japan Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Biosimilars Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Biosimilars Treatment Sales Value, 2019-2030
6.7.2 South Korea Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Biosimilars Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Biosimilars Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Biosimilars Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Biosimilars Treatment Sales Value, 2019-2030
6.9.2 India Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Biosimilars Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bayer
7.1.1 Bayer Profile
7.1.2 Bayer Main Business
7.1.3 Bayer Biosimilars Treatment Products, Services and Solutions
7.1.4 Bayer Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Bayer Recent Developments
7.2 Eli Lily, Inc.
7.2.1 Eli Lily, Inc. Profile
7.2.2 Eli Lily, Inc. Main Business
7.2.3 Eli Lily, Inc. Biosimilars Treatment Products, Services and Solutions
7.2.4 Eli Lily, Inc. Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Eli Lily, Inc. Recent Developments
7.3 Pfizer, Inc.
7.3.1 Pfizer, Inc. Profile
7.3.2 Pfizer, Inc. Main Business
7.3.3 Pfizer, Inc. Biosimilars Treatment Products, Services and Solutions
7.3.4 Pfizer, Inc. Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Sandoz International GmbH Recent Developments
7.4 Sandoz International GmbH
7.4.1 Sandoz International GmbH Profile
7.4.2 Sandoz International GmbH Main Business
7.4.3 Sandoz International GmbH Biosimilars Treatment Products, Services and Solutions
7.4.4 Sandoz International GmbH Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Sandoz International GmbH Recent Developments
7.5 Teva Pharmaceutical Industries Limited
7.5.1 Teva Pharmaceutical Industries Limited Profile
7.5.2 Teva Pharmaceutical Industries Limited Main Business
7.5.3 Teva Pharmaceutical Industries Limited Biosimilars Treatment Products, Services and Solutions
7.5.4 Teva Pharmaceutical Industries Limited Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Teva Pharmaceutical Industries Limited Recent Developments
7.6 Amgen Inc.
7.6.1 Amgen Inc. Profile
7.6.2 Amgen Inc. Main Business
7.6.3 Amgen Inc. Biosimilars Treatment Products, Services and Solutions
7.6.4 Amgen Inc. Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Amgen Inc. Recent Developments
7.7 Biocon
7.7.1 Biocon Profile
7.7.2 Biocon Main Business
7.7.3 Biocon Biosimilars Treatment Products, Services and Solutions
7.7.4 Biocon Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Biocon Recent Developments
7.8 Dr. Reddy’s Laboratories
7.8.1 Dr. Reddy’s Laboratories Profile
7.8.2 Dr. Reddy’s Laboratories Main Business
7.8.3 Dr. Reddy’s Laboratories Biosimilars Treatment Products, Services and Solutions
7.8.4 Dr. Reddy’s Laboratories Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Dr. Reddy’s Laboratories Recent Developments
7.9 Roche Ltd.
7.9.1 Roche Ltd. Profile
7.9.2 Roche Ltd. Main Business
7.9.3 Roche Ltd. Biosimilars Treatment Products, Services and Solutions
7.9.4 Roche Ltd. Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Roche Ltd. Recent Developments
7.10 Celltrion, Inc.
7.10.1 Celltrion, Inc. Profile
7.10.2 Celltrion, Inc. Main Business
7.10.3 Celltrion, Inc. Biosimilars Treatment Products, Services and Solutions
7.10.4 Celltrion, Inc. Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 Celltrion, Inc. Recent Developments
7.11 Samsung Bioepis
7.11.1 Samsung Bioepis Profile
7.11.2 Samsung Bioepis Main Business
7.11.3 Samsung Bioepis Biosimilars Treatment Products, Services and Solutions
7.11.4 Samsung Bioepis Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 Samsung Bioepis Recent Developments
8 Industry Chain Analysis
8.1 Biosimilars Treatment Industrial Chain
8.2 Biosimilars Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Biosimilars Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Biosimilars Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Biosimilars Treatment Product Introduction
1.2 Global Biosimilars Treatment Market Size Forecast
1.3 Biosimilars Treatment Market Trends & Drivers
1.3.1 Biosimilars Treatment Industry Trends
1.3.2 Biosimilars Treatment Market Drivers & Opportunity
1.3.3 Biosimilars Treatment Market Challenges
1.3.4 Biosimilars Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Biosimilars Treatment Players Revenue Ranking (2023)
2.2 Global Biosimilars Treatment Revenue by Company (2019-2024)
2.3 Key Companies Biosimilars Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Biosimilars Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Biosimilars Treatment
2.6 Biosimilars Treatment Market Competitive Analysis
2.6.1 Biosimilars Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Biosimilars Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Recombinant Non – Glycosylated Proteins
3.1.2 Recombinant Glycosylated Proteins
3.1.3 Recombinant Peptides
3.2 Global Biosimilars Treatment Sales Value by Type
3.2.1 Global Biosimilars Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Biosimilars Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Biosimilars Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Oncology
4.1.2 Chronic and Autoimmune Disease
4.1.3 Blood Disorders
4.1.4 Growth Hormone Disease
4.1.5 Infectious Disease
4.2 Global Biosimilars Treatment Sales Value by Application
4.2.1 Global Biosimilars Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Biosimilars Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Biosimilars Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Biosimilars Treatment Sales Value by Region
5.1.1 Global Biosimilars Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Biosimilars Treatment Sales Value by Region (2019-2024)
5.1.3 Global Biosimilars Treatment Sales Value by Region (2025-2030)
5.1.4 Global Biosimilars Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Biosimilars Treatment Sales Value, 2019-2030
5.2.2 North America Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Biosimilars Treatment Sales Value, 2019-2030
5.3.2 Europe Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Biosimilars Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Biosimilars Treatment Sales Value, 2019-2030
5.5.2 South America Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Biosimilars Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Biosimilars Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Biosimilars Treatment Sales Value
6.3 United States
6.3.1 United States Biosimilars Treatment Sales Value, 2019-2030
6.3.2 United States Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Biosimilars Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Biosimilars Treatment Sales Value, 2019-2030
6.4.2 Europe Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Biosimilars Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Biosimilars Treatment Sales Value, 2019-2030
6.5.2 China Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Biosimilars Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Biosimilars Treatment Sales Value, 2019-2030
6.6.2 Japan Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Biosimilars Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Biosimilars Treatment Sales Value, 2019-2030
6.7.2 South Korea Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Biosimilars Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Biosimilars Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Biosimilars Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Biosimilars Treatment Sales Value, 2019-2030
6.9.2 India Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Biosimilars Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bayer
7.1.1 Bayer Profile
7.1.2 Bayer Main Business
7.1.3 Bayer Biosimilars Treatment Products, Services and Solutions
7.1.4 Bayer Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Bayer Recent Developments
7.2 Eli Lily, Inc.
7.2.1 Eli Lily, Inc. Profile
7.2.2 Eli Lily, Inc. Main Business
7.2.3 Eli Lily, Inc. Biosimilars Treatment Products, Services and Solutions
7.2.4 Eli Lily, Inc. Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Eli Lily, Inc. Recent Developments
7.3 Pfizer, Inc.
7.3.1 Pfizer, Inc. Profile
7.3.2 Pfizer, Inc. Main Business
7.3.3 Pfizer, Inc. Biosimilars Treatment Products, Services and Solutions
7.3.4 Pfizer, Inc. Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Sandoz International GmbH Recent Developments
7.4 Sandoz International GmbH
7.4.1 Sandoz International GmbH Profile
7.4.2 Sandoz International GmbH Main Business
7.4.3 Sandoz International GmbH Biosimilars Treatment Products, Services and Solutions
7.4.4 Sandoz International GmbH Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Sandoz International GmbH Recent Developments
7.5 Teva Pharmaceutical Industries Limited
7.5.1 Teva Pharmaceutical Industries Limited Profile
7.5.2 Teva Pharmaceutical Industries Limited Main Business
7.5.3 Teva Pharmaceutical Industries Limited Biosimilars Treatment Products, Services and Solutions
7.5.4 Teva Pharmaceutical Industries Limited Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Teva Pharmaceutical Industries Limited Recent Developments
7.6 Amgen Inc.
7.6.1 Amgen Inc. Profile
7.6.2 Amgen Inc. Main Business
7.6.3 Amgen Inc. Biosimilars Treatment Products, Services and Solutions
7.6.4 Amgen Inc. Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Amgen Inc. Recent Developments
7.7 Biocon
7.7.1 Biocon Profile
7.7.2 Biocon Main Business
7.7.3 Biocon Biosimilars Treatment Products, Services and Solutions
7.7.4 Biocon Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Biocon Recent Developments
7.8 Dr. Reddy’s Laboratories
7.8.1 Dr. Reddy’s Laboratories Profile
7.8.2 Dr. Reddy’s Laboratories Main Business
7.8.3 Dr. Reddy’s Laboratories Biosimilars Treatment Products, Services and Solutions
7.8.4 Dr. Reddy’s Laboratories Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Dr. Reddy’s Laboratories Recent Developments
7.9 Roche Ltd.
7.9.1 Roche Ltd. Profile
7.9.2 Roche Ltd. Main Business
7.9.3 Roche Ltd. Biosimilars Treatment Products, Services and Solutions
7.9.4 Roche Ltd. Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Roche Ltd. Recent Developments
7.10 Celltrion, Inc.
7.10.1 Celltrion, Inc. Profile
7.10.2 Celltrion, Inc. Main Business
7.10.3 Celltrion, Inc. Biosimilars Treatment Products, Services and Solutions
7.10.4 Celltrion, Inc. Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 Celltrion, Inc. Recent Developments
7.11 Samsung Bioepis
7.11.1 Samsung Bioepis Profile
7.11.2 Samsung Bioepis Main Business
7.11.3 Samsung Bioepis Biosimilars Treatment Products, Services and Solutions
7.11.4 Samsung Bioepis Biosimilars Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 Samsung Bioepis Recent Developments
8 Industry Chain Analysis
8.1 Biosimilars Treatment Industrial Chain
8.2 Biosimilars Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Biosimilars Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Biosimilars Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Biosimilars Treatment Market Trends
Table 2. Biosimilars Treatment Market Drivers & Opportunity
Table 3. Biosimilars Treatment Market Challenges
Table 4. Biosimilars Treatment Market Restraints
Table 5. Global Biosimilars Treatment Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Biosimilars Treatment Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Biosimilars Treatment Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Biosimilars Treatment Product Type
Table 9. Key Companies Time to Begin Mass Production of Biosimilars Treatment
Table 10. Global Biosimilars Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars Treatment as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Biosimilars Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Biosimilars Treatment Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Biosimilars Treatment Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Biosimilars Treatment Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Biosimilars Treatment Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Biosimilars Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Biosimilars Treatment Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Biosimilars Treatment Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Biosimilars Treatment Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Biosimilars Treatment Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Biosimilars Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Biosimilars Treatment Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Biosimilars Treatment Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Biosimilars Treatment Sales Value by Region (2019-2024) & (%)
Table 27. Global Biosimilars Treatment Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Biosimilars Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Biosimilars Treatment Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Biosimilars Treatment Sales Value, (2025-2030) & (US$ Million)
Table 31. Bayer Basic Information List
Table 32. Bayer Description and Business Overview
Table 33. Bayer Biosimilars Treatment Products, Services and Solutions
Table 34. Revenue (US$ Million) in Biosimilars Treatment Business of Bayer (2019-2024)
Table 35. Bayer Recent Developments
Table 36. Eli Lily, Inc. Basic Information List
Table 37. Eli Lily, Inc. Description and Business Overview
Table 38. Eli Lily, Inc. Biosimilars Treatment Products, Services and Solutions
Table 39. Revenue (US$ Million) in Biosimilars Treatment Business of Eli Lily, Inc. (2019-2024)
Table 40. Eli Lily, Inc. Recent Developments
Table 41. Pfizer, Inc. Basic Information List
Table 42. Pfizer, Inc. Description and Business Overview
Table 43. Pfizer, Inc. Biosimilars Treatment Products, Services and Solutions
Table 44. Revenue (US$ Million) in Biosimilars Treatment Business of Pfizer, Inc. (2019-2024)
Table 45. Pfizer, Inc. Recent Developments
Table 46. Sandoz International GmbH Basic Information List
Table 47. Sandoz International GmbH Description and Business Overview
Table 48. Sandoz International GmbH Biosimilars Treatment Products, Services and Solutions
Table 49. Revenue (US$ Million) in Biosimilars Treatment Business of Sandoz International GmbH (2019-2024)
Table 50. Sandoz International GmbH Recent Developments
Table 51. Teva Pharmaceutical Industries Limited Basic Information List
Table 52. Teva Pharmaceutical Industries Limited Description and Business Overview
Table 53. Teva Pharmaceutical Industries Limited Biosimilars Treatment Products, Services and Solutions
Table 54. Revenue (US$ Million) in Biosimilars Treatment Business of Teva Pharmaceutical Industries Limited (2019-2024)
Table 55. Teva Pharmaceutical Industries Limited Recent Developments
Table 56. Amgen Inc. Basic Information List
Table 57. Amgen Inc. Description and Business Overview
Table 58. Amgen Inc. Biosimilars Treatment Products, Services and Solutions
Table 59. Revenue (US$ Million) in Biosimilars Treatment Business of Amgen Inc. (2019-2024)
Table 60. Amgen Inc. Recent Developments
Table 61. Biocon Basic Information List
Table 62. Biocon Description and Business Overview
Table 63. Biocon Biosimilars Treatment Products, Services and Solutions
Table 64. Revenue (US$ Million) in Biosimilars Treatment Business of Biocon (2019-2024)
Table 65. Biocon Recent Developments
Table 66. Dr. Reddy’s Laboratories Basic Information List
Table 67. Dr. Reddy’s Laboratories Description and Business Overview
Table 68. Dr. Reddy’s Laboratories Biosimilars Treatment Products, Services and Solutions
Table 69. Revenue (US$ Million) in Biosimilars Treatment Business of Dr. Reddy’s Laboratories (2019-2024)
Table 70. Dr. Reddy’s Laboratories Recent Developments
Table 71. Roche Ltd. Basic Information List
Table 72. Roche Ltd. Description and Business Overview
Table 73. Roche Ltd. Biosimilars Treatment Products, Services and Solutions
Table 74. Revenue (US$ Million) in Biosimilars Treatment Business of Roche Ltd. (2019-2024)
Table 75. Roche Ltd. Recent Developments
Table 76. Celltrion, Inc. Basic Information List
Table 77. Celltrion, Inc. Description and Business Overview
Table 78. Celltrion, Inc. Biosimilars Treatment Products, Services and Solutions
Table 79. Revenue (US$ Million) in Biosimilars Treatment Business of Celltrion, Inc. (2019-2024)
Table 80. Celltrion, Inc. Recent Developments
Table 81. Samsung Bioepis Basic Information List
Table 82. Samsung Bioepis Description and Business Overview
Table 83. Samsung Bioepis Biosimilars Treatment Products, Services and Solutions
Table 84. Revenue (US$ Million) in Biosimilars Treatment Business of Samsung Bioepis (2019-2024)
Table 85. Samsung Bioepis Recent Developments
Table 86. Key Raw Materials Lists
Table 87. Raw Materials Key Suppliers Lists
Table 88. Biosimilars Treatment Downstream Customers
Table 89. Biosimilars Treatment Distributors List
Table 90. Research Programs/Design for This Report
Table 91. Key Data Information from Secondary Sources
Table 92. Key Data Information from Primary Sources
Table 93. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Biosimilars Treatment Product Picture
Figure 2. Global Biosimilars Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Biosimilars Treatment Sales Value (2019-2030) & (US$ Million)
Figure 4. Biosimilars Treatment Report Years Considered
Figure 5. Global Biosimilars Treatment Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Biosimilars Treatment Revenue in 2023
Figure 7. Biosimilars Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Recombinant Non – Glycosylated Proteins Picture
Figure 9. Recombinant Glycosylated Proteins Picture
Figure 10. Recombinant Peptides Picture
Figure 11. Global Biosimilars Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 12. Global Biosimilars Treatment Sales Value Market Share by Type, 2023 & 2030
Figure 13. Product Picture of Oncology
Figure 14. Product Picture of Chronic and Autoimmune Disease
Figure 15. Product Picture of Blood Disorders
Figure 16. Product Picture of Growth Hormone Disease
Figure 17. Product Picture of Infectious Disease
Figure 18. Global Biosimilars Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Biosimilars Treatment Sales Value Market Share by Application, 2023 & 2030
Figure 20. North America Biosimilars Treatment Sales Value (2019-2030) & (US$ Million)
Figure 21. North America Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
Figure 22. Europe Biosimilars Treatment Sales Value (2019-2030) & (US$ Million)
Figure 23. Europe Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
Figure 24. Asia Pacific Biosimilars Treatment Sales Value (2019-2030) & (US$ Million)
Figure 25. Asia Pacific Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
Figure 26. South America Biosimilars Treatment Sales Value (2019-2030) & (US$ Million)
Figure 27. South America Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
Figure 28. Middle East & Africa Biosimilars Treatment Sales Value (2019-2030) & (US$ Million)
Figure 29. Middle East & Africa Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
Figure 30. Key Countries/Regions Biosimilars Treatment Sales Value (%), (2019-2030)
Figure 31. United States Biosimilars Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 32. United States Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
Figure 33. United States Biosimilars Treatment Sales Value by Application (%), 2023 VS 2030
Figure 34. Europe Biosimilars Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 35. Europe Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
Figure 36. Europe Biosimilars Treatment Sales Value by Application (%), 2023 VS 2030
Figure 37. China Biosimilars Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 38. China Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
Figure 39. China Biosimilars Treatment Sales Value by Application (%), 2023 VS 2030
Figure 40. Japan Biosimilars Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 41. Japan Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
Figure 42. Japan Biosimilars Treatment Sales Value by Application (%), 2023 VS 2030
Figure 43. South Korea Biosimilars Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 44. South Korea Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
Figure 45. South Korea Biosimilars Treatment Sales Value by Application (%), 2023 VS 2030
Figure 46. Southeast Asia Biosimilars Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 47. Southeast Asia Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
Figure 48. Southeast Asia Biosimilars Treatment Sales Value by Application (%), 2023 VS 2030
Figure 49. India Biosimilars Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 50. India Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
Figure 51. India Biosimilars Treatment Sales Value by Application (%), 2023 VS 2030
Figure 52. Biosimilars Treatment Industrial Chain
Figure 53. Biosimilars Treatment Manufacturing Cost Structure
Figure 54. Channels of Distribution (Direct Sales, and Distribution)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Table 1. Biosimilars Treatment Market Trends
Table 2. Biosimilars Treatment Market Drivers & Opportunity
Table 3. Biosimilars Treatment Market Challenges
Table 4. Biosimilars Treatment Market Restraints
Table 5. Global Biosimilars Treatment Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Biosimilars Treatment Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Biosimilars Treatment Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Biosimilars Treatment Product Type
Table 9. Key Companies Time to Begin Mass Production of Biosimilars Treatment
Table 10. Global Biosimilars Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars Treatment as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Biosimilars Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Biosimilars Treatment Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Biosimilars Treatment Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Biosimilars Treatment Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Biosimilars Treatment Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Biosimilars Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Biosimilars Treatment Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Biosimilars Treatment Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Biosimilars Treatment Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Biosimilars Treatment Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Biosimilars Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Biosimilars Treatment Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Biosimilars Treatment Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Biosimilars Treatment Sales Value by Region (2019-2024) & (%)
Table 27. Global Biosimilars Treatment Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Biosimilars Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Biosimilars Treatment Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Biosimilars Treatment Sales Value, (2025-2030) & (US$ Million)
Table 31. Bayer Basic Information List
Table 32. Bayer Description and Business Overview
Table 33. Bayer Biosimilars Treatment Products, Services and Solutions
Table 34. Revenue (US$ Million) in Biosimilars Treatment Business of Bayer (2019-2024)
Table 35. Bayer Recent Developments
Table 36. Eli Lily, Inc. Basic Information List
Table 37. Eli Lily, Inc. Description and Business Overview
Table 38. Eli Lily, Inc. Biosimilars Treatment Products, Services and Solutions
Table 39. Revenue (US$ Million) in Biosimilars Treatment Business of Eli Lily, Inc. (2019-2024)
Table 40. Eli Lily, Inc. Recent Developments
Table 41. Pfizer, Inc. Basic Information List
Table 42. Pfizer, Inc. Description and Business Overview
Table 43. Pfizer, Inc. Biosimilars Treatment Products, Services and Solutions
Table 44. Revenue (US$ Million) in Biosimilars Treatment Business of Pfizer, Inc. (2019-2024)
Table 45. Pfizer, Inc. Recent Developments
Table 46. Sandoz International GmbH Basic Information List
Table 47. Sandoz International GmbH Description and Business Overview
Table 48. Sandoz International GmbH Biosimilars Treatment Products, Services and Solutions
Table 49. Revenue (US$ Million) in Biosimilars Treatment Business of Sandoz International GmbH (2019-2024)
Table 50. Sandoz International GmbH Recent Developments
Table 51. Teva Pharmaceutical Industries Limited Basic Information List
Table 52. Teva Pharmaceutical Industries Limited Description and Business Overview
Table 53. Teva Pharmaceutical Industries Limited Biosimilars Treatment Products, Services and Solutions
Table 54. Revenue (US$ Million) in Biosimilars Treatment Business of Teva Pharmaceutical Industries Limited (2019-2024)
Table 55. Teva Pharmaceutical Industries Limited Recent Developments
Table 56. Amgen Inc. Basic Information List
Table 57. Amgen Inc. Description and Business Overview
Table 58. Amgen Inc. Biosimilars Treatment Products, Services and Solutions
Table 59. Revenue (US$ Million) in Biosimilars Treatment Business of Amgen Inc. (2019-2024)
Table 60. Amgen Inc. Recent Developments
Table 61. Biocon Basic Information List
Table 62. Biocon Description and Business Overview
Table 63. Biocon Biosimilars Treatment Products, Services and Solutions
Table 64. Revenue (US$ Million) in Biosimilars Treatment Business of Biocon (2019-2024)
Table 65. Biocon Recent Developments
Table 66. Dr. Reddy’s Laboratories Basic Information List
Table 67. Dr. Reddy’s Laboratories Description and Business Overview
Table 68. Dr. Reddy’s Laboratories Biosimilars Treatment Products, Services and Solutions
Table 69. Revenue (US$ Million) in Biosimilars Treatment Business of Dr. Reddy’s Laboratories (2019-2024)
Table 70. Dr. Reddy’s Laboratories Recent Developments
Table 71. Roche Ltd. Basic Information List
Table 72. Roche Ltd. Description and Business Overview
Table 73. Roche Ltd. Biosimilars Treatment Products, Services and Solutions
Table 74. Revenue (US$ Million) in Biosimilars Treatment Business of Roche Ltd. (2019-2024)
Table 75. Roche Ltd. Recent Developments
Table 76. Celltrion, Inc. Basic Information List
Table 77. Celltrion, Inc. Description and Business Overview
Table 78. Celltrion, Inc. Biosimilars Treatment Products, Services and Solutions
Table 79. Revenue (US$ Million) in Biosimilars Treatment Business of Celltrion, Inc. (2019-2024)
Table 80. Celltrion, Inc. Recent Developments
Table 81. Samsung Bioepis Basic Information List
Table 82. Samsung Bioepis Description and Business Overview
Table 83. Samsung Bioepis Biosimilars Treatment Products, Services and Solutions
Table 84. Revenue (US$ Million) in Biosimilars Treatment Business of Samsung Bioepis (2019-2024)
Table 85. Samsung Bioepis Recent Developments
Table 86. Key Raw Materials Lists
Table 87. Raw Materials Key Suppliers Lists
Table 88. Biosimilars Treatment Downstream Customers
Table 89. Biosimilars Treatment Distributors List
Table 90. Research Programs/Design for This Report
Table 91. Key Data Information from Secondary Sources
Table 92. Key Data Information from Primary Sources
Table 93. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Biosimilars Treatment Product Picture
Figure 2. Global Biosimilars Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Biosimilars Treatment Sales Value (2019-2030) & (US$ Million)
Figure 4. Biosimilars Treatment Report Years Considered
Figure 5. Global Biosimilars Treatment Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Biosimilars Treatment Revenue in 2023
Figure 7. Biosimilars Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Recombinant Non – Glycosylated Proteins Picture
Figure 9. Recombinant Glycosylated Proteins Picture
Figure 10. Recombinant Peptides Picture
Figure 11. Global Biosimilars Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 12. Global Biosimilars Treatment Sales Value Market Share by Type, 2023 & 2030
Figure 13. Product Picture of Oncology
Figure 14. Product Picture of Chronic and Autoimmune Disease
Figure 15. Product Picture of Blood Disorders
Figure 16. Product Picture of Growth Hormone Disease
Figure 17. Product Picture of Infectious Disease
Figure 18. Global Biosimilars Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Biosimilars Treatment Sales Value Market Share by Application, 2023 & 2030
Figure 20. North America Biosimilars Treatment Sales Value (2019-2030) & (US$ Million)
Figure 21. North America Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
Figure 22. Europe Biosimilars Treatment Sales Value (2019-2030) & (US$ Million)
Figure 23. Europe Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
Figure 24. Asia Pacific Biosimilars Treatment Sales Value (2019-2030) & (US$ Million)
Figure 25. Asia Pacific Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
Figure 26. South America Biosimilars Treatment Sales Value (2019-2030) & (US$ Million)
Figure 27. South America Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
Figure 28. Middle East & Africa Biosimilars Treatment Sales Value (2019-2030) & (US$ Million)
Figure 29. Middle East & Africa Biosimilars Treatment Sales Value by Country (%), 2023 VS 2030
Figure 30. Key Countries/Regions Biosimilars Treatment Sales Value (%), (2019-2030)
Figure 31. United States Biosimilars Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 32. United States Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
Figure 33. United States Biosimilars Treatment Sales Value by Application (%), 2023 VS 2030
Figure 34. Europe Biosimilars Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 35. Europe Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
Figure 36. Europe Biosimilars Treatment Sales Value by Application (%), 2023 VS 2030
Figure 37. China Biosimilars Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 38. China Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
Figure 39. China Biosimilars Treatment Sales Value by Application (%), 2023 VS 2030
Figure 40. Japan Biosimilars Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 41. Japan Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
Figure 42. Japan Biosimilars Treatment Sales Value by Application (%), 2023 VS 2030
Figure 43. South Korea Biosimilars Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 44. South Korea Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
Figure 45. South Korea Biosimilars Treatment Sales Value by Application (%), 2023 VS 2030
Figure 46. Southeast Asia Biosimilars Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 47. Southeast Asia Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
Figure 48. Southeast Asia Biosimilars Treatment Sales Value by Application (%), 2023 VS 2030
Figure 49. India Biosimilars Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 50. India Biosimilars Treatment Sales Value by Type (%), 2023 VS 2030
Figure 51. India Biosimilars Treatment Sales Value by Application (%), 2023 VS 2030
Figure 52. Biosimilars Treatment Industrial Chain
Figure 53. Biosimilars Treatment Manufacturing Cost Structure
Figure 54. Channels of Distribution (Direct Sales, and Distribution)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
DigitalBroadcast and Cinematography Cameras Lease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Mobile and Web Event Analytics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Business Information - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232